Department of Chemistry, School of Advanced Sciences, VIT, Vellore-632014, Tamil Nadu, India.
Dalton Trans. 2021 Feb 14;50(6):2268-2283. doi: 10.1039/d0dt03586f. Epub 2021 Jan 28.
Cancer is the most incurable pernicious disease to date after cardiovascular disease with an immeasurable rate of mortality. However, effective cancer medication and therapy are still castles in the sky to researchers. Therefore, in search of an appropriate strategy to annihilate cancer, we have designed a set of Ir(iii)-Cp* dipyridophenazine complexes as luminescent anticancer agents combining the cancer inhibiting potency of the planar dipyridophenazine (dppz) moiety through DNA interaction and mitochondrial dysfunction with the wonderful photoluminescence ability and target specificity of iridium metal. Hence, with the synergy of these dual aspects in the same system, we have aspired to emphasize the theranostic approach of cancer treatment in the present study by preparing effective, aqueous-soluble, mitochondria-targeting, highly cytoselective, luminescent, cancer cell-permeable scaffolds, enabling diagnosis as well as the healing of cancer cells in the body. Here, the presence of the cyclopentadienyl (Cp*) moiety in association with the fluorine group has boosted the lipophilic character of the complexes. Also, the cytotoxicity screening of the prepared CpIr(iii)-dipyridophenazine complexes (IrL1-IrL7) against colorectal adenocarcinoma cells (Caco-2) and human epitheloid cervix carcinoma cells (HeLa) clearly identified them as potential anticancer agents and imaging studies unveiled their superb cellular imaging properties. Among them, the complex [(η-Cp)IrCl(11-fluorodipyrido[3,2-a:2',3'-c]phenazine)] (IrL6) achieved the best cytoselectivity. However, the superiority of the anticancer potency of [(η-Cp*)IrCl(benzo[i]dipyrido[3,2-a:2',3'-c]phenazine)] (IrL3) was also corroborated by its activity against the most aggressive colorectal carcinoma cell line (HT-29), whereas (η-Cp*)IrCl(11-(trifluoromethyl)dipyrido[3,2-a:2',3'-c]phenazine (IrL5) came into the limelight as the best theranostic agent as it showed remarkable cytoselectivity as well as significant cellular imaging properties, endowing it with the highest quantum yield value among all the complexes.
癌症是继心血管疾病之后目前最无法治愈的恶性疾病,死亡率极高。然而,有效的癌症药物和治疗方法对研究人员来说仍然是空中楼阁。因此,为了寻找消灭癌症的合适策略,我们设计了一系列 Ir(iii)-Cp二吡啶并苯嗪配合物作为发光抗癌剂,将平面二吡啶并苯嗪 (dppz) 部分通过 DNA 相互作用和线粒体功能障碍抑制癌症的能力与铱金属的美妙光致发光能力和靶向特异性结合在一起。因此,通过在同一系统中结合这两个方面的协同作用,我们希望通过制备有效的、水溶性的、靶向线粒体的、高度细胞选择性的、发光的、可穿透癌细胞的支架,强调癌症治疗的诊断和治疗方法,从而强调癌症治疗的诊断和治疗方法。在本研究中,配合物中存在环戊二烯基 (Cp) 部分和氟基团增强了配合物的亲脂性。此外,对制备的 CpIr(iii)-二吡啶并苯嗪配合物 (IrL1-IrL7) 对结肠直肠腺癌细胞 (Caco-2) 和人上皮样宫颈癌细胞 (HeLa) 的细胞毒性筛选清楚地表明它们是潜在的抗癌剂,并且成像研究揭示了它们出色的细胞成像特性。其中,配合物 [(η-Cp)IrCl(11-氟二吡啶并[3,2-a:2',3'-c]苯嗪)] (IrL6) 表现出最好的细胞选择性。然而,[(η-Cp*)IrCl(苯并[i]二吡啶并[3,2-a:2',3'-c]苯嗪)] (IrL3) 的抗癌活性也得到了证实,因为它对最具侵袭性的结肠直肠癌细胞系 (HT-29) 具有活性,而 (η-Cp*)IrCl(11-(三氟甲基)二吡啶并[3,2-a:2',3'-c]苯嗪 (IrL5) 作为最佳治疗剂脱颖而出,因为它表现出显著的细胞选择性和显著的细胞成像特性,使其在所有配合物中具有最高的量子产率值。